Acadia Pharmaceuticals
ACAD Nasdaq· Pharmaceuticals
Last close · Oct 26, 2026
$19.74
KIRA · Stoqly’s AI analyst, in plain words
- Acadia Pharmaceuticals had $1.1B of revenue in fiscal 2025, up 11.9% on the year before. Over five years, revenue changed +19.4% a year on average.
- Its operating margin was 9.8%, down 14.3 pts: of every 100 in sales, about 10 is left after running the business.
- Acadia Pharmaceuticals made $391M of net profit in fiscal 2025.
- Free cash flow was $105M in fiscal 2025, 9.8% of revenue.
- Acadia Pharmaceuticals returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 2.1%.
Market cap
$3.4B
P/E
8.9x
Revenue
$1.1B
Net income
$391M
Free cash flow
$105M
Operating margin
9.8%
Acadia Pharmaceuticals in 30 seconds · fiscal 2025
Are sales growing?
+11.9%
Yes. Sales grew 11.9% last year.
Does it make a profit?
36.5%
Yes. It keeps 36.5% of every sale as profit.
Does profit turn into cash?
9.8%
Partly. 9.8% of sales ends up as free cash.
How is the share priced?
8.9x
One share costs 8.9 times its yearly profit per share. Typical for its sector: 28.4x.
What Acadia Pharmaceuticals does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- ACADIA PHARMACEUTICALS INC.
- CIK
- 0001070494
Acadia Pharmaceuticals · ACAD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $484M | $517M | $726M | $958M | $1.1B |
| Revenue growth | 9.6% | 6.8% | 40.5% | 31.9% | 11.9% |
| Gross margin | 97.8% | 98.0% | 94.3% | 91.5% | 91.7% |
| Operating margin | −35.2% | −43.2% | −10.1% | 24.1% | 9.8% |
| Net income | −$168M | −$216M | −$61.3M | $227M | $391M |
| Net margin | −34.7% | −41.8% | −8.4% | 23.6% | 36.5% |
| Diluted EPS | −$1.05 | −$1.34 | −$0.37 | $1.36 | $2.30 |
| Cash | |||||
| Cash from operations | −$126M | −$114M | $16.7M | $158M | $110M |
| Capital expenditure | $1.1M | $0.0M | $0.0M | $0.5M | $4.7M |
| Free cash flow | −$127M | −$114M | $16.7M | $157M | $105M |
| FCF margin | −26.2% | −22.1% | 2.3% | 16.4% | 9.8% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 2.0% | 0.7% | 1.3% | 1.6% | 2.1% |
| Debt and strength | |||||
| Cash and short-term investments | $521M | $417M | $439M | $756M | $820M |
| Shareholders' equity | $541M | $400M | $432M | $733M | $1.2B |
| Current ratio | 6.4x | 4.0x | 2.4x | 2.4x | 3.8x |
| Returns and quality | |||||
| Return on equity | −28.8% | −45.9% | −14.7% | 38.9% | 39.9% |
| Altman Z'' | −3.2 | −9.2 | −6.6 | −0.1 | 3.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.4M
6 insiders
Of sales under plans
77%
$2.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Acadia Pharmaceuticals · ACAD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals ACAD | $3.4B | 11.9% | 9.8% | 9.8% | — | 8.9x | — |
| Indivior INDV | $4.3B | 4.3% | 21.2% | −7.5% | — | 12.4x | 4 |
| ANI Pharmaceuticals ANIP | $1.6B | 43.8% | 12.6% | 19.4% | 15.9% | 15.7x | 6 |
| Collegium Pharmaceutical COLL | $754M | 23.6% | 23.0% | 42.0% | 53.4% | 18.7x | 6 |
| Alkermes ALKS | $7.7B | −5.3% | 17.2% | 32.6% | — | 116.9x | — |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $19.74 a share, the company is worth $3.4B: 8.9 times its earnings of the last four quarters.
Acadia Pharmaceuticals grew sales faster than 2 of its 4 similar companies. Its P/E is higher than 0 of 4.
Source: SEC EDGAR XBRL filings (CIK 0001070494). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.